Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Report 2026

Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview

• Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion market size has reached to $51.8 billion in 2025 • Expected to grow to $101.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Rising Obesity And Diabetes Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Advanced Weight Management And Blood Glucose Control Therapies • Market Trend: Innovative Receptor Agonist Therapies Strengthening Cardiometabolic Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market?

Glucagon-like peptide-1 (GLP-1) cardiometabolic expansion refers to the broadening role of GLP-1–targeted therapies beyond their initial metabolic applications into a wider range of cardiometabolic health areas. This expansion is driven by growing scientific and clinical evidence demonstrating the ability of GLP-1 pathway modulation to influence multiple interconnected physiological functions. The main drug types of glucagon-like peptide-1 (GLP-1) cardiometabolic expansion include glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 dual agonists, and glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide oral therapies. Glucagon-like peptide-1 receptor agonists refer to therapeutic agents that mimic the action of the GLP-1 hormone to improve metabolic and cardiovascular outcomes. These therapies are used across indications including heart failure with preserved ejection fraction, peripheral artery disease, cardiovascular risk reduction, non-alcoholic steatohepatitis, and chronic kidney disease and are utilized by end users including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

What Is The Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Growth Forecast?

The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market size is expected to see rapid growth in the next few years. It will grow to $101.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of cardiometabolic indications beyond diabetes, increasing adoption of combination incretin therapies, growth in preventive cardiology approaches, rising healthcare focus on obesity-driven comorbidities, integration of precision medicine in metabolic disease treatment. Major trends in the forecast period include expansion of glp-1 therapies into cardiovascular and chronic kidney disease management, increasing adoption of combination incretin therapies for multi-target cardiometabolic control, rising use of glp-1 drugs in obesity-related cardiometabolic risk reduction programs, growth of real-world evidence studies validating long-term cardioprotective benefits of glp-1 agents, increasing integration of glp-1 therapies into digital chronic disease management platforms.

Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Segmentation

1) By Drug Type: Glucagon-Like Peptide-1 Receptor Agonists; Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists; Glucagon-Like Peptide-1 Or Glucose-Dependent Insulinotropic Polypeptide Oral Therapies 2) By Indication: Heart Failure With Preserved Ejection Fraction; Peripheral Artery Disease; Cardiovascular Risk Reduction; Non-Alcoholic Steatohepatitis; Chronic Kidney Disease 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes Subsegments: 1) By Glucagon-Like Peptide-1 Receptor Agonists: Short-Acting Glucagon-Like Peptide-1 Receptor Agonists; Long-Acting Glucagon-Like Peptide-1 Receptor Agonists; Weekly Glucagon-Like Peptide-1 Receptor Agonists; Daily Glucagon-Like Peptide-1 Receptor Agonists 2) By Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists: Injectable Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Oral Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Long-Acting Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists

What Is The Driver Of The Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market?

The rising obesity and diabetes prevalence is expected to propel the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market going forward. Obesity and diabetes are chronic metabolic disorders that increase body fat levels and impair the body’s ability to regulate blood glucose effectively. The rise in obesity and diabetes is increasing due to reduced physical activity and growing sedentary lifestyles across global populations. The prevalence of obesity and diabetes is increasing the demand for glucagon-like peptide-1 (GLP-1) cardiometabolic therapies, as these drugs help manage blood glucose levels, promote weight reduction, and improve overall cardiometabolic health. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency responsible for disease prevention and health promotion, 23 US states reported adult obesity prevalence rates above 35% in 2023, compared to 22 states in 2022. Therefore, the rising obesity and diabetes prevalence is driving the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market.

Key Players In The Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

Major companies operating in the glucagon-like peptide-1(glp-1) cardiometabolic expansion market are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Zealand Pharma A/S; Innovent Biologics Inc.; Huadong Medicine Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Sciwind Biosciences Co. Ltd.; Ascletis Pharma Inc.; F. Hoffmann-La Roche AG; Pfizer Inc.; Sanofi S.A.; Regeneron Pharmaceuticals Inc.; Eccogene Inc.; Gan & Lee Pharmaceuticals Co. Ltd.; Altimmune Inc.

Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Trends and Insights

Major companies operating in the glucagon-like-peptide (GLP-1) cardiometabolic expansion market are focusing on developing innovative products, such as dual and multi-agonist receptor drugs, to enhance weight reduction outcomes, improve metabolic control, and extend therapeutic benefits beyond diabetes into cardiovascular and obesity-related disease management. Dual and multi-agonist receptor drugs refer to therapies that simultaneously activate two or more hormone receptors, such as GLP-1, GIP, or glucagon receptors, to improve metabolic functions including blood sugar control, weight loss, and energy balance. For instance, in November 2023, Eli Lilly, a US-based pharmaceutical company, launched Zepbound (tirzepatide) in the United States for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This marked the first approval of a dual GIP Or GLP-1 receptor agonist for obesity, significantly expanding the GLP-1 cardiometabolic treatment landscape beyond diabetes into large-scale weight management and metabolic disease intervention.

What Are Latest Mergers And Acquisitions In The Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market?

In December 2024, Novo Holdings, a Denmark-based life sciences investment company, acquired Catalent for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen production capabilities for Novo Nordisk’s GLP-1 obesity and diabetes therapies by securing critical fill-finish manufacturing facilities and expanding manufacturing capacity for incretin-based treatments. Catalent is a US-based company specializing in fill-finish, formulation, peptide development, and production services for GLP-1 and other cardiometabolic drugs.

Regional Outlook

North America was the largest region in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market?

The glucagon-like peptide-1 (glp-1) cardiometabolic expansion market consists of semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, and lixisenatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Report 2026?

The glucagon-like peptide-1(glp-1) cardiometabolic expansion market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide-1(glp-1) cardiometabolic expansion industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.